Four biotech Nasdaq wannabes outline IPO plans — and don't miss Chi-Med's HKEX pitch
If the string of biotech IPO filings the Nasdaq saw on market close Friday says anything other than that the window for public fundraising remains wide open, it’s about the diversity of areas these aspiring public drugmakers operate in — from immuno-oncology and Alzheimer’s to diabetic complications and cardio indications.
Keep scrolling to read about the latest marquee Chinese biopharma to file for a listing at the Hong Kong stock exchange — further defusing early worries that the city’s loosened rules for biotechs might not be enough to attract top players.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.